Saluda Medical

Saluda Medical is a privately held company headquartered in Bloomington, Minnesota, with a global reach. Employing 486 individuals, the company generated $20.2 million in revenue. Saluda Medical is dedicated to revolutionizing neuromodulation therapies, focusing on advanced closed-loop technologies to address debilitating neurological disorders. The company's flagship product, the Evoke® System, is a closed-loop spinal cord stimulation (SCS) system designed to manage chronic intractable pain in the trunk and/or limbs. Indicated for use in conditions such as failed back surgery syndrome, intractable low back pain, and leg pain, the Evoke System continuously monitors and adjusts stimulation levels based on the patient's response, offering optimized pain relief. The system's efficacy has been demonstrated in groundbreaking clinical trials, with 12-month results published in The Lancet Neurology and 24-month results in JAMA Neurology. The Evoke System stands out as the only ECAP-controlled closed-loop SCS system available. Its innovative design allows for instantaneous reading and response to nerve activity, surpassing the capabilities of traditional open-loop SCS for overall trunk and/or limb pain management. The system has received CE Mark approval in the European Union and FDA approval in the United States, with a full commercial release planned for 2023 in the U.S. For more information about Saluda Medical and the Evoke System, including risks and safety information, visit www.saludamedical.com.